Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study
Background and objectives: Inhibition of programed death -1and programed death ligand-1 pathway enhances antitumor activity of T lymphocytes, therefore, provides a new strategy for tumor treatment utilizing immunotherapy. The aim of this study to assess the frequency of programed death ligand-1 exp...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kurdistan Higher Council Of Medical Specialties
2024-06-01
|
| Series: | Advanced Medical Journal |
| Subjects: | |
| Online Access: | https://amj.khcms.edu.krd/index.php/main/article/view/430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197919323389952 |
|---|---|
| author | Zainab Mohammed Ali Rafil Toma Yaqo Alaa Hani Raziq |
| author_facet | Zainab Mohammed Ali Rafil Toma Yaqo Alaa Hani Raziq |
| author_sort | Zainab Mohammed Ali |
| collection | DOAJ |
| description |
Background and objectives: Inhibition of programed death -1and programed death ligand-1 pathway enhances antitumor activity of T lymphocytes, therefore, provides a new strategy for tumor treatment utilizing immunotherapy. The aim of this study to assess the frequency of programed death ligand-1 expression in renal cell carcinoma by using the immunohistochemistry and to correlate the results the clinicopathologic parameters.
Methods: This is a cross sectional retrospective study performed in Duhok City from 2017-2022 on fifty-four formalin fixed paraffin embedded blocks of nephrectomy specimens diagnosed as renal cell carcinoma and collected from central lab of Duhok and some private labs. Two sections were prepared from each block, one section was stained with hematoxylin and eosin for histological analysis and the other one was used for immunohistochemical assessment of programed death ligand-1then the results were correlated with various clinicopathological parameters.
Results: Programed death ligand -1; membranous expression was positive in 19 cases (35.2%) of renal cell carcinoma out of 54 cases. There was no significant correlation between programed death ligand -1 expression and age (p= 0.991), gender (p= 0.272), multifocality (p= 0.607), tumor size (p= 0.796), histological subtype (p= 0.107), tumor stage (p= 0.546), nuclear grade (p= 0.781), surgical margins involvement (p= 0.119) and lymphovascular invasion (p= 0.4), but there was statistically significant correlation with nodal metastases (p= 0.039).
Conclusion: Programmed death ligand -1/ Combined positive score was ?1 in about one third (35.2%) of renal cell carcinoma cases and this result can be utilized for the provision of immune checkpoint inhibitor (ICIs), regardless the age, gender, histological type, stage, nuclear grade, and the presence of lymphovascular invasion (LVI).
|
| format | Article |
| id | doaj-art-c9158e4ebfdd48d4b0ed79bd12f7f41b |
| institution | OA Journals |
| issn | 2958-8979 2957-3580 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Kurdistan Higher Council Of Medical Specialties |
| record_format | Article |
| series | Advanced Medical Journal |
| spelling | doaj-art-c9158e4ebfdd48d4b0ed79bd12f7f41b2025-08-20T02:12:59ZengKurdistan Higher Council Of Medical SpecialtiesAdvanced Medical Journal2958-89792957-35802024-06-019210.56056/amj.2024.270431Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort studyZainab Mohammed Ali0Rafil Toma Yaqo1Alaa Hani Raziq2M.B.Ch. B, DOH-Duhok, Directory of health. MBChB, FIBMS, Lecturer, Pathology Department, College of Medicine-Duhok UniversityMBChB, MSc, FIBMS, Professor & Consultant Pathologist, Pathology Department, College of Medicine-Duhok University Background and objectives: Inhibition of programed death -1and programed death ligand-1 pathway enhances antitumor activity of T lymphocytes, therefore, provides a new strategy for tumor treatment utilizing immunotherapy. The aim of this study to assess the frequency of programed death ligand-1 expression in renal cell carcinoma by using the immunohistochemistry and to correlate the results the clinicopathologic parameters. Methods: This is a cross sectional retrospective study performed in Duhok City from 2017-2022 on fifty-four formalin fixed paraffin embedded blocks of nephrectomy specimens diagnosed as renal cell carcinoma and collected from central lab of Duhok and some private labs. Two sections were prepared from each block, one section was stained with hematoxylin and eosin for histological analysis and the other one was used for immunohistochemical assessment of programed death ligand-1then the results were correlated with various clinicopathological parameters. Results: Programed death ligand -1; membranous expression was positive in 19 cases (35.2%) of renal cell carcinoma out of 54 cases. There was no significant correlation between programed death ligand -1 expression and age (p= 0.991), gender (p= 0.272), multifocality (p= 0.607), tumor size (p= 0.796), histological subtype (p= 0.107), tumor stage (p= 0.546), nuclear grade (p= 0.781), surgical margins involvement (p= 0.119) and lymphovascular invasion (p= 0.4), but there was statistically significant correlation with nodal metastases (p= 0.039). Conclusion: Programmed death ligand -1/ Combined positive score was ?1 in about one third (35.2%) of renal cell carcinoma cases and this result can be utilized for the provision of immune checkpoint inhibitor (ICIs), regardless the age, gender, histological type, stage, nuclear grade, and the presence of lymphovascular invasion (LVI). https://amj.khcms.edu.krd/index.php/main/article/view/430PD-1PDL-1Renal cell carcinoma |
| spellingShingle | Zainab Mohammed Ali Rafil Toma Yaqo Alaa Hani Raziq Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study Advanced Medical Journal PD-1 PDL-1 Renal cell carcinoma |
| title | Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study |
| title_full | Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study |
| title_fullStr | Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study |
| title_full_unstemmed | Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study |
| title_short | Programmed death ligand I (PDL-1) Expression in renal cell carcinoma: A retrospective cohort study |
| title_sort | programmed death ligand i pdl 1 expression in renal cell carcinoma a retrospective cohort study |
| topic | PD-1 PDL-1 Renal cell carcinoma |
| url | https://amj.khcms.edu.krd/index.php/main/article/view/430 |
| work_keys_str_mv | AT zainabmohammedali programmeddeathligandipdl1expressioninrenalcellcarcinomaaretrospectivecohortstudy AT rafiltomayaqo programmeddeathligandipdl1expressioninrenalcellcarcinomaaretrospectivecohortstudy AT alaahaniraziq programmeddeathligandipdl1expressioninrenalcellcarcinomaaretrospectivecohortstudy |